Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-02 | Mr. Dalton E. SmartSenior VP of Finance, Principal Accounting Officer & Global Controller | 251,00 | 28,15k | Derivative Exercise and Retained Stock | 112,16 | 9,39k | 2,75% |
| 2026-05-02 | Mr. Dalton E. SmartSenior VP of Finance, Principal Accounting Officer & Global Controller | -132,00 | 0,00 | Derivative Exercise and Sale | 112,16 | 9,39k | - |
| 2026-05-02 | Mr. David R. MaraldoExec. VP & President of Merck Manufacturing Division | 393,00 | 44,08k | Derivative Exercise and Retained Stock | 112,16 | 26,57k | 1,50% |
| 2026-05-02 | Mr. David R. MaraldoExec. VP & President of Merck Manufacturing Division | -159,00 | 0,00 | Derivative Exercise and Sale | 112,16 | 26,57k | - |
| 2026-04-29 | Mr. Chirfi GuindoExec. VP of Strategic Access, Policy & Communications | 998,00 | 109,81k | Derivative Exercise and Retained Stock | 110,03 | 61,67k | 1,64% |
| 2026-04-29 | Mr. Chirfi GuindoExec. VP of Strategic Access, Policy & Communications | -969,00 | 0,00 | Derivative Exercise and Sale | 110,03 | 61,67k | - |
| 2026-04-29 | Mr. Sanat ChattopadhyayInitié | 1,47k | 161,41k | Derivative Exercise and Retained Stock | 110,03 | 200,68k | 0,74% |
| 2026-04-29 | Mr. Sanat ChattopadhyayInitié | -1,13k | 0,00 | Derivative Exercise and Sale | 110,03 | 200,68k | - |
| 2026-04-29 | Mr. Richard R. DeLucaExec. VP & President of Merck Animal Health | 1,28k | 140,51k | Derivative Exercise and Retained Stock | 110,03 | 162,86k | 0,79% |
| 2026-04-29 | Mr. Richard R. DeLucaExec. VP & President of Merck Animal Health | -1,24k | 0,00 | Derivative Exercise and Sale | 110,03 | 162,86k | - |
| 2026-04-29 | Mr. David Michael WilliamsExec. VP and Chief Information & Digital Officer | 698,00 | 76,80k | Derivative Exercise and Retained Stock | 110,03 | 31,72k | 2,25% |
| 2026-04-29 | Mr. David Michael WilliamsExec. VP and Chief Information & Digital Officer | -679,00 | 0,00 | Derivative Exercise and Sale | 110,03 | 31,72k | - |
| 2026-04-29 | Mr. Dalton E. SmartSenior VP of Finance, Principal Accounting Officer & Global Controller | -483,00 | 0,00 | Derivative Exercise and Sale | 110,03 - 110,95 | 9,14k | - |
| 2026-04-29 | Mr. Dalton E. SmartSenior VP of Finance, Principal Accounting Officer & Global Controller | 925,00 | 102,06k | Derivative Exercise and Retained Stock | 110,03 - 110,95 | 9,14k | 11,26% |
| 2026-04-29 | Dr. Dean Y. LiExec. VP & President of Merck Research Laboratories | 2,40k | 263,63k | Derivative Exercise and Retained Stock | 110,03 | 94,43k | 2,60% |
| 2026-04-29 | Dr. Dean Y. LiExec. VP & President of Merck Research Laboratories | -2,33k | 0,00 | Derivative Exercise and Sale | 110,03 | 94,43k | - |
| 2026-04-29 | Ms. Jennifer L. ZacharyExec. VP & General Counsel | 1,50k | 164,71k | Derivative Exercise and Retained Stock | 110,03 | 70,90k | 2,16% |
| 2026-04-29 | Ms. Jennifer L. ZacharyExec. VP & General Counsel | -1,45k | 0,00 | Derivative Exercise and Sale | 110,03 | 70,90k | - |
| 2026-04-29 | Ms. Betty D. LarsonExec. VP & Chief HR Officer | 7,58k | 839,41k | Derivative Exercise and Retained Stock | 110,03 - 110,95 | 13,77k | 122,27% |
| 2026-04-29 | Ms. Betty D. LarsonExec. VP & Chief HR Officer | -5,86k | 0,00 | Derivative Exercise and Sale | 110,03 - 110,95 | 13,77k | - |
| 2026-04-29 | Ms. Caroline A. LitchfieldExec. VP & CFO | 2,00k | 219,73k | Derivative Exercise and Retained Stock | 110,03 | 92,30k | 2,21% |
| 2026-04-29 | Ms. Caroline A. LitchfieldExec. VP & CFO | -1,94k | 0,00 | Derivative Exercise and Sale | 110,03 | 92,30k | - |
| 2026-04-29 | Mr. Robert M. DavisChairman, President & CEO | 6,75k | 742,59k | Derivative Exercise and Retained Stock | 110,03 | 450,35k | 1,52% |
| 2026-04-29 | Mr. Robert M. DavisChairman, President & CEO | -6,55k | 0,00 | Derivative Exercise and Sale | 110,03 | 450,35k | - |
| 2026-04-29 | Mr. Johannes J. OosthuizenExec. VP and President of Oncology & MSD International | 698,00 | 76,80k | Derivative Exercise and Retained Stock | 110,03 | 21,90k | 3,29% |
| 2026-04-29 | Mr. Johannes J. OosthuizenExec. VP and President of Oncology & MSD International | -679,00 | 0,00 | Derivative Exercise and Sale | 110,03 | 21,90k | - |
| 2026-02-12 | Mr. Chirfi GuindoExec. VP of Strategic Access, Policy & Communications | -10,00k | 1,21M | Vente | 121,46 | 60,62k | -14,16% |
| 2026-02-10 | Dr. Dean Y. LiExec. VP & President of Merck Research Laboratories | -10,24k | 1,20M | Vente | 117,52 | 92,04k | -10,01% |
| 2026-02-09 | Mr. Chirfi GuindoExec. VP of Strategic Access, Policy & Communications | -10,00k | 1,18M | Vente | 118,41 | 70,62k | -12,40% |
| 2026-02-09 | Ms. Jennifer L. ZacharyExec. VP & General Counsel | -121,57k | 0,00 | Derivative Exercise and Sale | 119,15 | 68,92k | - |
| 2026-02-06 | Mr. David Michael WilliamsExec. VP and Chief Information & Digital Officer | -5,00k | 221,43k | Derivative Exercise and Sale | 77,62 - 121,91 | 30,84k | - |
| 2026-02-04 | Mr. Dalton E. SmartSenior VP of Finance, Principal Accounting Officer & Global Controller | -4,00k | 230,42k | Derivative Exercise and Sale | 62,07 - 119,68 | 8,21k | - |
| 2026-02-04 | Mr. Dalton E. SmartSenior VP of Finance, Principal Accounting Officer & Global Controller | -2,40k | 287,22k | Vente | 119,68 | 8,21k | -22,63% |
| 2026-02-06 | Mr. Johannes J. OosthuizenExec. VP and President of Oncology & MSD International | -15,00k | 1,83M | Vente | 121,87 | 21,20k | -41,44% |
| 2026-02-04 | Ms. Caroline A. LitchfieldExec. VP & CFO | -42,00k | 2,79M | Derivative Exercise and Sale | 53,06 - 119,61 | 90,19k | - |
| 2026-02-04 | Dr. Dean Y. LiExec. VP & President of Merck Research Laboratories | -15,09k | 946,35k | Derivative Exercise and Sale | 56,04 - 118,77 | 102,27k | - |
| 2026-02-05 | Mr. Chirfi GuindoExec. VP of Strategic Access, Policy & Communications | -20,00k | 2,44M | Vente | 121,88 | 80,62k | -19,88% |
| 2026-02-06 | Mr. Richard R. DeLucaExec. VP & President of Merck Animal Health | -37,69k | 4,56M | Vente | 120,92 | 160,17k | -19,05% |
| 2026-02-04 | Mr. Robert M. DavisChairman, President & CEO | -47,43k | 5,60M | Vente | 117,38 - 118,35 | 443,60k | -9,66% |
| 2025-11-10 | Ms. Cristal N. DowningInitié | -7,09k | 616,40k | Vente | 87,00 | 0,00 | -100,00% |
| 2025-11-03 | Mr. David Michael WilliamsExec. VP and Chief Information & Digital Officer | -8,61k | 720,04k | Vente | 83,59 | 24,58k | -25,95% |
| 2025-08-04 | Mr. David Michael WilliamsExec. VP and Chief Information & Digital Officer | 8,69k | 688,79k | Derivative Exercise and Retained Stock | 79,29 | 33,01k | 35,71% |
| 2025-08-04 | Mr. David Michael WilliamsExec. VP and Chief Information & Digital Officer | -8,43k | 0,00 | Derivative Exercise and Sale | 79,29 | 33,01k | - |
| 2025-08-04 | Mr. Chirfi GuindoExec. VP of Strategic Access, Policy & Communications | 18,73k | 1,48M | Derivative Exercise and Retained Stock | 79,29 | 89,29k | 26,54% |
| 2025-08-04 | Mr. Chirfi GuindoExec. VP of Strategic Access, Policy & Communications | -18,18k | 0,00 | Derivative Exercise and Sale | 79,29 | 89,29k | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
